Simulations Plus Releases GastroPlus™ 8.5

Before you go, we thought you'd like these...
Before you go close icon

Simulations Plus Releases GastroPlus™ 8.5

Software Upgrade Adds Numerous Capabilities and User Convenience Features

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NAS: SLP) , a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that it has released Version 8.5 of its industry-leading GastroPlus™ software program for the simulation of gastrointestinal absorption, pharmacokinetics, and pharmacodynamics.

Dr. Viera Lukacova, team leader for Simulation Technologies at Simulations Plus, said, "Version 8.5 is the result of many months of work by a number of our scientists and staff to add new functionalities and to respond to a variety of customer requests."

The total number of enhancements is too many to list here; however, the major new features are:

  • Infant physiologies in PBPKPlus™ now allow simulation of drug pharmacokinetics and pharmacodynamics in infants as young as 16 weeks premature, with automatic scaling of physiological parameters with age
  • Expression levels for UGT enzymes in human liver, kidney, and gut
  • Expression levels for sulfotransferases in human liver, kidney, and lung
  • Expression levels for CYP enzymes in dog liver and gut
  • Novel method for transporter in vitro-in vivo extrapolation (IVIVE)
  • A new precipitation model based on classical nucleation theory
  • Ability to change physiologies during a simulation (as in growth of an infant over weeks or months), and
  • Enhanced graphics for more insightful interpretation of simulation results

Dr. Lukacova continued, "In addition to the major features above, this release incorporates many more user convenience features, trapping of potential user mistakes with appropriate warnings, and fixing of some minor bugs. A new quality assurance testing protocol was implemented to ensure that this release performed properly across a variety of operating systems and in a variety of languages for our global customers. "

John DiBella, vice president for marketing and sales of Simulations Plus, added, "Our customers have been waiting for this release and we're pleased that it has finally passed all of our extensive testing with the many changes involved. We believe the additional capabilities in GastroPlus 8.5 add considerable value to our existing customers and will attract interest from an even wider audience in the pharmaceutical, food, and cosmetics industries."

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol "SLP." For more information, visit our Web site at

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 - With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like "believe," "expect" and "anticipate" mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.


Simulations Plus Investor Relations
Ms. Renée Bouché, 661-723-7723
Hayden IR
Mr. Cameron Donahue, 651-653-1854

KEYWORDS:   United States  North America  California


The article Simulations Plus Releases GastroPlus™ 8.5 originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading